334 related articles for article (PubMed ID: 22203604)
1. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
[TBL] [Abstract][Full Text] [Related]
2. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
3. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.
Shields RK; Nguyen MH; Press EG; Updike CL; Clancy CJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):6361-5. PubMed ID: 24060873
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
7. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.
Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
J Clin Microbiol; 2011 Feb; 49(2):624-9. PubMed ID: 21147948
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
[TBL] [Abstract][Full Text] [Related]
9. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
10. In vitro fungicidal activities of anidulafungin, caspofungin, and micafungin against Candida glabrata, Candida bracarensis, and Candida nivariensis evaluated by time-kill studies.
Gil-Alonso S; Jauregizar N; Cantón E; Eraso E; Quindós G
Antimicrob Agents Chemother; 2015; 59(6):3615-8. PubMed ID: 25801575
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
Bordallo-Cardona MÁ; Escribano P; de la Pedrosa EG; Marcos-Zambrano LJ; Cantón R; Bouza E; Guinea J
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872063
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.
Brzankalski GE; Najvar LK; Wiederhold NP; Bocanegra R; Fothergill AW; Rinaldi MG; Pattterson TF; Graybill JR
J Antimicrob Chemother; 2008 Nov; 62(5):1094-100. PubMed ID: 18658194
[TBL] [Abstract][Full Text] [Related]
14. Echinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.
Axner-Elings M; Botero-Kleiven S; Jensen RH; Arendrup MC
J Clin Microbiol; 2011 Jul; 49(7):2516-21. PubMed ID: 21543574
[TBL] [Abstract][Full Text] [Related]
15. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.
Wiederhold NP; Najvar LK; Bocanegra R; Molina D; Olivo M; Graybill JR
Antimicrob Agents Chemother; 2007 May; 51(5):1616-20. PubMed ID: 17307976
[TBL] [Abstract][Full Text] [Related]
17. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
[TBL] [Abstract][Full Text] [Related]
18. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
[TBL] [Abstract][Full Text] [Related]
19. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.
Ruan SY; Chu CC; Hsueh PR
Antimicrob Agents Chemother; 2008 Aug; 52(8):2919-22. PubMed ID: 18458136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
